Given your experience with amikacin liposome inhalation suspension in the setting of early severe and/or treatment refractory MAC lung disease, can you discuss the design, efficacy, safety, results, and clinical applications of the CONVERT trial?

Given your experience with amikacin liposome inhalation suspension in the setting of early severe and/or treatment refractory MAC lung disease, can you discuss the design, efficacy, safety, results, and clinical applications of the CONVERT trial?

CLICK HERE FOR CME CREDIT

Given your experience with amikacin liposome inhalation suspension in the setting of early severe and/or treatment refractory MAC lung disease, can you discuss the design, efficacy, safety, results, and clinical applications of the CONVERT trial?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina